Presentations on Friday, March 23th
EMBRACE II: Accreditation and patient accrual
EMBRACE I: Data completeness, database dump
EMBRACE II morbidity
EMBRACE morbidity general remarks
EMBRACE I morbidity reporting
Morbidity scoring workshop
EMBRACE II Brachytherapy contouring dummy run
Experience from CBCT monitoring (organ filling and ITV margins) (1)
Experience from CBCT monitoring (organ filling and ITV margins) (2)
Contouring workshop EBRT and BT
IQ EMBRACE and imaging workshops
Translational research
Prospective protocol in vaginal cancer
Presentations on Saturday, March 24th
EMBRACE II EBRT dose planning dummy run
Feedback to centers EBRT and BT dose and volume parameters (monitoring): EMBRACE I and EMBRACE II (1)
Feedback to centers EBRT and BT dose and volume parameters (monitoring): EMBRACE I and EMBRACE II (2)
EBRT and BT treatment planning workshop (1)
EBRT and BT treatment planning workshop (2)
EMBRACE I research: Bladder toxicity: risk factors and multivariable analysis
EMBRACE I research: TRAK, isodose surface volume and technique (Monica Serban)
EMBRACE I research: Impact of bladder trigone dose
EMBRACE I research: Small tumours and dose
EMBRACE I research: FIGO/TNM stages
EMBRACE I research: LAPERS – PROM results in EMBRACE
PRO-CTCAE and EORTC reporting: sub-study
EMBRACE I+II roadmap and organization